Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Glenmark Pharmaceuticals won Innovation of the Year award
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Subscribe To Our Newsletter & Stay Updated
